GlaxoSmithKline submits application for COPD drug in EU

GlaxoSmithKline (GSK) has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease (COPD).

GlaxoSmithKline (GSK) has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease (COPD).

The treatment, which is administered using the company's Ellipta inhaler, is designed to relive symptoms in adult suffers of COPD.

The group said a marketing authoristion application (MAA) for the treatment has been submitted to the European Medicines Agency (EMA).

Regulatory filings for the product are imminent in the US and planned in other countries during the course of 2013, it added.

The share price was down 0.36% to 1,676p by 11:00 on Friday.

NR

Most Popular

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism
Economy

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism

Russell Napier talks to Merryn about financial repression – or "stealing money from old people slowly" – plus how Asian capitalism is taking over in t…
16 Jul 2021
Three companies that are reaping the rewards of investment
Share tips

Three companies that are reaping the rewards of investment

Professional investor Edward Wielechowski of the Odyssean Investment Trust highlights three stocks that have have invested well – and are able to deal…
19 Jul 2021
The future belongs to emerging markets – three EM stocks to buy now
Share tips

The future belongs to emerging markets – three EM stocks to buy now

Professional investor Carlos von Hardenberg of Mobius Capital Partners picks three of his favourite emerging-market stocks.
5 Jul 2021